Looking forward to 2016, I wondered which Biotechs I would watch closely. Here’s my list (which is not meant to be extensive and is in no particular order):
1. Immunocore – Oxford, UK
Immunocore is developing TCR-based immuno-oncology treatments and has raised nearly €300M ($320M) in its last round of private fundraising – a pure anomaly for the European standard.
ImmTACs are a novel class of biologic drugs based on the Company’s proprietary T cell receptor (TCR) technology, which have the potential to treat diseases with high unmet medical need including cancer, viral infections and autoimmune diseases.
2016 will be a year with high expectation for the company (from the public and the investors who invested so much) and lot will be going on.
- Click to read our exclusive interview of the CBO of Immunocore
- Read out Review on How Biotech has Changed Cancer Treatments (e.g. TCR)
2. Enterome – Paris,